From Surf Wiki (app.surf) — the open knowledge base
European Federation of Pharmaceutical Industries and Associations
Brussels-based trade association
Brussels-based trade association
| Field | Value |
|---|---|
| name | EFPIA |
| full_name | European Federation of Pharmaceutical Industries and Associations |
| logo | European Federation of Pharmaceutical Industries and Associations logo.svg |
| formation | 1978 |
| founding_location | Brussels, Belgium |
| purpose | Trade association |
| location_city | Brussels |
| location_country | Belgium |
| region_served | Europe |
| membership | 37 national associations, 55 corporate members |
| key_people | Nathalie Moll (General Director) |
| Lars Fruergaard Jørgensen (Chairman of the Board) | |
| staff | 60 |
| staff_year | 2023 |
| website |
Lars Fruergaard Jørgensen (Chairman of the Board) The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association and lobbying organisation, founded in 1978 and representing the pharmaceutical industry operating in Europe. Through its membership of 36 national associations and 39 leading pharmaceutical companies, the EFPIA represents 1,900 European companies.
EFPIA priorities
EFPIA priorities include speeding up regulatory approval and reimbursement processes for new medicines, creating a strong science base in Europe, joining forces with key stakeholders on political issues concerning health and addressing safety concerns. EFPIA also includes specialised groups like Vaccines Europe who produce approximately 80% of vaccines used worldwide and European Biopharmaceutical Enterprises harness biotechnology to develop approximately one-fifth of new medicines.
Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is a public-private partnership designed by the European Commission and EFPIA. It is a pan-European collaboration that brings together large biopharmaceutical companies, small- and medium-sized enterprises (SMEs), patient organisations, academia, hospitals and public authorities. The initiative aims to accelerate the discovery and development of better medicines by removing bottlenecks in the drug development process. It focuses on creating better methods and tools to improve and enhance the drug development process, rather than developing specific, new medicines.
Controversy
From 1991 to 1998 Emer Cooke worked for the EFPIA. She became executive director of the European Medicines Agency (EMA), an agency of the European Union (EU) in charge of the evaluation and supervision of medicinal products, in November 2020.
In a session of the Austrian Parliament member of parliament Gerald Hauser on 1 April 2021 publicly criticised a potential conflict of interest, by her allowing the controversial Oxford–AstraZeneca COVID-19 vaccine to be approved, while having worked for the very same industry in the past as a lobbyist of the EFPIA.
References
References
- "Board & Working Parties".
- "Who we are".
- "Vaccines Europe".
- "WHO | Emer Cooke".
- (16 November 2020). "Emer Cooke takes office as head of EMA {{!}} European Medicines Agency".
- "FPÖ – Hauser: EMA-Direktorin hat ihr ganzes Arbeitsleben mit Lobbying für die Pharmaindustrie verbracht {{!".
- "Gerald Hauser zeigt Brisantes über die Impfstoffzulassung auf!".
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about European Federation of Pharmaceutical Industries and Associations — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report